Back to today’s briefing

Story perspectives

Newronika's AlphaDBS: Game-Changer for Parkinson’s Treatment

3/26/2025

50 5

Summary

Story summary

Newronika is set to revolutionize Parkinson’s treatment with the launch of AlphaDBS, an innovative deep brain stimulation system, now cleared for select European markets after earning CE Mark approval. This milestone ensures it meets stringent EU safety standards, while plans for a pivotal clinical trial in the U.S. are underway, following FDA investigational device exemption approval.

1 of 1

Story summary

Newronika is set to revolutionize Parkinson’s treatment with the launch of AlphaDBS, an innovative deep brain stimulation system, now cleared for select European markets after earning CE Mark approval. This milestone ensures it meets stringent EU safety standards, while plans for a pivotal clinical trial in the U.S. are underway, following FDA investigational device exemption approval.